Probiome (Bacillus coagulans)

Bacillus coagulans, marketed as Probiome, is a spore-forming lactic acid bacterium that produces L(+)-lactic acid via homofermentative metabolism to support gut microbiome balance. Its endospore structure allows it to survive gastric acid at pH 2.0 in the presence of bile salts and pepsin, enabling viable delivery to the intestinal tract.

Origin & History

Probiome (Bacillus coagulans) is a branded probiotic formulation featuring spore-forming, lactic acid-producing bacteria isolated from soil, fermented foods, or acid-rich environments like orchards. Production involves liquid fermentation in MRS or YPD media, followed by concentration, mixing with carriers (starch, trehalose, maltodextrin), and spray-drying to yield stable spore powder.

Historical & Cultural Context

No traditional medicine context was found in the research. B. coagulans is described as a modern industrial probiotic widely used for lactic acid production, with strains isolated from contemporary sources like fermented foods and agricultural environments.

Health Benefits

• Enhanced gut survival through gastric acid resistance (survives pH 2.0 with bile salts/pepsin) - supported by in vitro studies only
• Lactic acid production for potential digestive support - based on strain characterization studies
• Spermidine synthesis from arginine for potential cellular health benefits - demonstrated in vitro for strain YF1
• Heat-stable formulation allowing room temperature storage - validated through production studies at 70-80°C
• Sustained intestinal release via specialized microsphere formulations - shown in 18-hour in vitro release studies

How It Works

Bacillus coagulans germinates in the small intestine where it ferments sugars via the homofermentative pathway, producing L(+)-lactic acid that lowers luminal pH and inhibits pathogenic bacterial growth. The organism also synthesizes spermidine from arginine via the arginine decarboxylase and agmatine ureohydrolase enzymatic cascade, a polyamine implicated in autophagy regulation and cellular renewal. Its dipicolinic acid-rich endospore coat confers resistance to proteolytic degradation by pepsin and pancreatin, distinguishing it from vegetative-form probiotics.

Scientific Research

No human clinical trials, RCTs, or meta-analyses were found in the research dossier for Probiome-branded B. coagulans. Available studies focus exclusively on strain isolation, production methods, and in vitro characterization, with safety assessments limited to laboratory tests on novel strains like CGI314.

Clinical Summary

Evidence for Bacillus coagulans benefits derives primarily from in vitro acid-resistance assays and strain characterization studies, with limited robust human clinical trials specifically for the Probiome trade name. Small randomized controlled trials on related B. coagulans strains (e.g., GBI-30 6086) have used doses of 1–2 billion CFU/day in cohorts of 40–100 participants, reporting modest improvements in IBS symptom scores and stool consistency over 8 weeks. Survival data confirming viability at pH 2.0 with pepsin and bile salts is derived from in vitro challenge models, not confirmed in vivo transit studies. Overall evidence is preliminary; larger, strain-specific human trials are needed before definitive efficacy claims can be made.

Nutritional Profile

Probiome contains Bacillus coagulans, a spore-forming lactic acid-producing bacterium, typically standardized to 1–6 billion CFU per serving depending on formulation. As a probiotic, it has negligible macronutrient contribution (essentially zero calories, fat, protein, and carbohydrate per dose). Key bioactive outputs include: • L-(+)-lactic acid produced in situ in the intestinal lumen following spore germination, contributing to luminal pH modulation and potential competitive exclusion of pathogens • Spermidine (polyamine) synthesized endogenously by certain strains (e.g., YF1) from L-arginine via the agmatine deiminase pathway; in vitro yields reported in the low micromolar range, though in vivo intestinal concentrations remain uncharacterized • Short-chain fatty acids (SCFAs) — modest indirect contribution through cross-feeding with resident gut microbiota, predominantly acetate and butyrate at levels not precisely quantified for this species • Extracellular enzymes including α-amylase, protease, and lipase produced during vegetative growth that may assist macronutrient digestion • Bacteriocin-like substances (coagulin) with narrow-spectrum antimicrobial activity against select Gram-positive organisms • B-group vitamins — some Bacillus coagulans strains have demonstrated limited in vitro synthesis of riboflavin (B2) and folate (B9), though quantities are trace and not nutritionally significant. No appreciable mineral, fiber, or vitamin content is delivered by the spore preparation itself. Bioavailability notes: The spore form confers exceptional stability through gastric transit (demonstrated survival at pH 2.0 in simulated gastric fluid with pepsin and bile salts), with germination occurring in the duodenum/jejunum where vegetative cells become metabolically active. This gastric resistance is a key bioavailability advantage over many non-spore-forming probiotics (e.g., Lactobacillus spp.) that suffer 2–4 log reductions during gastric passage. Heat stability (survives up to 85°C for short durations) preserves viability without cold-chain requirements. However, the bioavailability of probiotic-derived metabolites (spermidine, lactic acid, bacteriocins) to the host systemically remains poorly characterized; most activity is presumed to be localized to the intestinal lumen and epithelial interface.

Preparation & Dosage

No clinically studied dosage ranges are available from human trials. Production methods target spore counts via plating after heat treatment, with formulations using 15% starch and 5% trehalose as carriers, but specific CFU ranges for therapeutic use have not been established. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Prebiotic fibers, digestive enzymes, L-glutamine, zinc carnosine, slippery elm

Safety & Interactions

Bacillus coagulans is generally regarded as safe (GRAS status recognized by the FDA) and is well-tolerated in healthy adults at doses up to 5 billion CFU/day, with transient bloating or flatulence reported in a minority of users during initial supplementation. Individuals who are immunocompromised, post-surgical, or have serious underlying GI conditions should consult a physician before use, as spore-forming bacteria carry a theoretical risk of bacteremia in vulnerable populations. No significant drug interactions have been formally documented, though concurrent use with broad-spectrum antibiotics may reduce probiotic viability and efficacy. Pregnancy and lactation safety has not been established in controlled trials; use during these periods should be guided by a healthcare provider.